Research programme: phosphatidylinositol 3 kinase inhibitors - Infinity Pharmaceuticals

Drug Profile

Research programme: phosphatidylinositol 3 kinase inhibitors - Infinity Pharmaceuticals

Alternative Names: INK 055; IPI-1828; IPI-443; phosphatidylinositol 3 kinase inhibitors - Intellikine

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellikine
  • Developer Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Takeda America Holdings
  • Class Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Haematological malignancies; Inflammation; Solid tumours

Most Recent Events

  • 31 Mar 2017 Infinity Pharmaceuticals has patents pending for compositions of matter, pharmaceutical compositions, methods of use and synthetic methods for PI3K-gamma programme in World
  • 28 Sep 2016 Phosphatidylinositol 3 kinase inhibitors are still in preclinical development for Haematological malignancies, Solid tumours, Autoimmune disorders and Inflammation in USA (Infinity Pharmaceuticals pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top